Home / BUSINESS / Granules India surges on getting USFDA’s approval for Acetaminophen Extended Release Tablets

Granules India surges on getting USFDA’s approval for Acetaminophen Extended Release Tablets

Mumbai : Granules India is currently trading at Rs. 115.90, up by 1.95 points or 1.71% from its previous closing of Rs. 113.95 on the BSE. The scrip opened at Rs. 114.95 and has touched a high and low of Rs. 116.25 and Rs. 114.95 respectively. So far 1601 shares were traded on the counter. The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 123.35 on 10-Sep-2018 and a 52 week low of Rs. 71.75 on 05-Jun-2018.

Last one week high and low of the scrip stood at Rs. 116.25 and Rs. 111.25 respectively. The current market cap of the company is Rs. 2897.15 crore. The promoters holding in the company stood at 42.90%, while Institutions and Non-Institutions held 15.78% and 41.32% respectively.

Granules India has received approval from US Food and Drug Administration (USFDA) for Abbreviated New Drug Application (ANDA) for Acetaminophen 650 mg Tablets, Extended Release, bioequivalent to the reference listed drug product (RLD), Tylenol 650mg tablets, Extended Release. The ANDA was filed by Granules Pharmaceuticals Inc., a wholly owned subsidiary of the company.

Acetaminophen 650 mg extended release tablets are used primarily for temporary pain management including arthritis relief. Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Please share this news